SARASOTA, Fla., May 22, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...
INVO Bioscience Reports First Quarter 2020 Financial Results
Company to Participate in Virtual Investor Conference on May 20 at 2:00pm ET (Details Below)SARASOTA, Fla., May 15, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility...
INVO Bioscience Appoints Christopher Myer as VP Business Development – Americas
SARASOTA, Fla., April 2, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on treating infertility with its FDA-cleared INVOcell® product, announced today the appointment of Christopher A. Myer as Vice President Business Development -...
INVO Bioscience Reports 2019 Financial Results
SARASOTA, Fla., March 30, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System,...
INVO Bioscience Changes Trading Symbol to “INVO” Effective March 16, 2020
INVO's novel, FDA-cleared INVOcell technology provides an in-vivo incubation solution which can help increase access and capacity to the large underserved global fertility marketSARASOTA, Fla., March 16, 2020 -- INVO Bioscience, Inc. (OTCQB: INVO) ("INVO"), a medical...